Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: an ambispective multicentre case series
British Journal of Dermatology · 18.02.2025 · 192 (3) · 501-509
DOI: 10.1093/bjd/ljae403 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Dermatology, online erschienen am 17.10.2024. Verfasst von Nidia Planella-Fontanillas und 38 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital del Mar Research Institute, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain. Hauptthemen laut MEDLINE: Pemphigoid, Bullous, Antibodies, Monoclonal, Humanized, Dermatologic Agents. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
Background
Bullous pemphigoid (BP) affects elderly individuals with multiple comorbidities, making conventional treatments unsuitable.
Objectives
Evaluate the effectiveness and safety of dupilumab in the treatment of BP.
Methods
A multicentre ambispective cohort study was conducted across 34 hospitals. Patients with BP treated with dupilumab were included. Most of the patients (97.1%) received an initial 600-mg dose followed by 300 mg every 2 weeks. The primary outcome was the proportion of patients achieving complete remission (CR) within 4 weeks, defined as an Investigator’s Global Assessment score of 0 or 1. CR at weeks 16, 24 and 52, adverse events (AEs), reductions in Peak Pruritus Numerical Rating Scale (PP-NRS) and systemic glucocorticoid use were also assessed.
Results
The study included 103 patients with a median age of 77.3 years; 58.3% were male. CR was achieved by 53.4% within 4 weeks and 95.7% by week 52. The PP-NRS score reduced by 70.0% by week 4 and was completely controlled by week 24. Thirteen patients presented with AEs, most of which were mild. Systemic glucocorticoid use reduced by 82.1% by week 52. Shorter disease duration and exclusive cutaneous involvement predicted better response at 16 weeks. No differences in response rates to dupilumab were observed between drug-associated BP and idiopathic cases. No significant difference in response rates was observed between patients treated with dupilumab in monotherapy and those receiving dupilumab with concomitant treatments.
Conclusions
Dupilumab is effective, rapid and safe in managing BP, reducing the need for corticosteroids and other treatments. Early initiation and exclusive skin involvement predict better outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Hospital del Mar Research Institute, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain.
- Department of Dermatology, Hospital Clínic de Barcelona, University of Barcelona, IDIBAPS, Barcelona, Spain.
ORCID-Profile: Nidia Planella-Fontanillas, Juan Luis Castaño Fernández, Francisco Javier Melgosa Ramos
Zitieren
APA
Planella-Fontanillas, N., Bosch-Amate, X., Jiménez Antón, A., Moreno-Vílchez, C., Guerrero, M. G., Blanes Martínez, M. D. M., Ballester Martínez, M. A., Bassas-Freixas, P., Castaño Fernández, J. L., Estébanez Corrales, A., Suarez Fernández, R., Santos Alarcón, S., Alonso, A. B., Torrent, M., Ballano Ruiz, A., Collantes Rodríguez, C., España, A., Fonseca Capdevila, E., Faure, I. G., …, & Curto-Barredo, L. (2025). Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: an ambispective multicentre case series. British Journal of Dermatology, 192(3), 501-509. https://doi.org/10.1093/bjd/ljae403
Vancouver
Planella-Fontanillas N, Bosch-Amate X, Jiménez Antón A, Moreno-Vílchez C, Guerrero MG, Blanes Martínez MDM, et al. Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: an ambispective multicentre case series. British Journal of Dermatology. 2025;192(3):501-509. doi:10.1093/bjd/ljae403
BibTeX
@article{PlanellaFontanillas2025,
author = {Planella-Fontanillas, Nidia and Bosch-Amate, Xavier and Jiménez Antón, Alicia and Moreno-Vílchez, Carlos and Guerrero, María Gamo and Blanes Martínez, María Del Mar and Ballester Martínez, María Asunción and Bassas-Freixas, Patricia and Castaño Fernández, Juan Luis and Estébanez Corrales, Andrea and Suarez Fernández, Ricardo and Santos Alarcón, Sergio and Alonso, Ana Bauzá and Torrent, Marina and Ballano Ruiz, Adrian and Collantes Rodríguez, Cristina and España, Agustín and Fonseca Capdevila, Eduardo and Faure, Inmaculada Gil and Hernández Fernández, Carlos Pelayo and Melgosa Ramos, Francisco Javier and Spertino, Jorge and Zaragoza Ninet, Violeta and Armillas, Lucia and Bielsa, Isabel and Carrera, Cristina and Esquius Rafat, Mireia and Fulgencio Barbarin, Jon and Fernandez Vela, Javier and Lova Navarro, Miguel and Martín Callizo, Clara and Martín-Sala, Sara and Ojeda, Rosa and Amer, Maria Elisabet Parera and Puigdollers, Anna Sánchez and Pujol, Ramon M and Podlipnik, Sebastian and Mascaró, José Manuel and Curto-Barredo, Laia},
title = {Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: an ambispective multicentre case series},
journal = {British Journal of Dermatology},
year = {2025},
volume = {192},
number = {3},
pages = {501--509},
doi = {10.1093/bjd/ljae403}
}
EUVIMED